<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037452</url>
  </required_header>
  <id_info>
    <org_study_id>145-G-201</org_study_id>
    <nct_id>NCT01037452</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of an antacid/Lansoprazole combination
      product for the relief of heartburn after consuming a heartburn-inducing meal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal</measure>
    <time_frame>1 day</time_frame>
    <description>Participant reported severity of heartburn using a Visual Analog Scale (VAS)directly on CRF every 15 minutes until no heartburn reported or up to 5 hours after 1st heartburn-inducing meal, whichever occurred first. At this point in time, a diary was provided to participants to record any changes in severity of heartburn for 28 hours post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Heartburn After the Heartburn-inducing Meals</measure>
    <time_frame>1 day</time_frame>
    <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Nighttime Heartburn</measure>
    <time_frame>1 day</time_frame>
    <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Number of Participants That Reported an Adverse Event for the Combination Product, PPI Alone, Antacid Alone and Placebo.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>Combination product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antacid alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium carbonate/magnesium hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Combination product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Tablet</description>
    <arm_group_label>PPI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium carbonate/magnesium hydroxide</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Antacid alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experiencing heartburn in the past month if untreated

          -  Having heartburn that responds to heartburn medication

          -  Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion
             in the study.

        Exclusion Criteria:

          -  Having history of erosive esophagitis or gastroesophageal reflux disease (GERD)
             diagnosed by a physician and confirmed by testing (endoscopy)

          -  Be unwilling to take only the study medication, and antacid provided as a rescue
             medication for relief of acute heartburn during the study.

        &quot;Other protocol-defined inclusion/exclusion criteria may apply&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis .</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <results_first_submitted>December 14, 2010</results_first_submitted>
  <results_first_submitted_qc>March 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2011</results_first_posted>
  <last_update_submitted>March 1, 2011</last_update_submitted>
  <last_update_submitted_qc>March 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Head, New Therapeutic Opportunities</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Heartburn</keyword>
  <keyword>antacid</keyword>
  <keyword>PPI</keyword>
  <keyword>Lansoprazole</keyword>
  <keyword>calcium carbonate</keyword>
  <keyword>magnesium hydroxide</keyword>
  <keyword>Relief of heartburn following ingestion of a heartburn-inducing meal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Antacids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Product</title>
          <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
        </group>
        <group group_id="P2">
          <title>PPI Alone</title>
          <description>Lansoprazole 15 mg, single dose</description>
        </group>
        <group group_id="P3">
          <title>Antacid Alone</title>
          <description>Calcium carbonate/magnesium hydroxide, single dose</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Product</title>
          <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
        </group>
        <group group_id="B2">
          <title>PPI Alone</title>
          <description>Lansoprazole 15 mg, single dose</description>
        </group>
        <group group_id="B3">
          <title>Antacid Alone</title>
          <description>Calcium carbonate/magnesium hydroxide, single dose</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo, single dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="11.5"/>
                    <measurement group_id="B2" value="30.4" spread="11.1"/>
                    <measurement group_id="B3" value="30.9" spread="13.3"/>
                    <measurement group_id="B4" value="31.9" spread="12.6"/>
                    <measurement group_id="B5" value="31.7" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal</title>
        <description>Participant reported severity of heartburn using a Visual Analog Scale (VAS)directly on CRF every 15 minutes until no heartburn reported or up to 5 hours after 1st heartburn-inducing meal, whichever occurred first. At this point in time, a diary was provided to participants to record any changes in severity of heartburn for 28 hours post treatment.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Product</title>
            <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
          </group>
          <group group_id="O2">
            <title>PPI Alone</title>
            <description>Lansoprazole 15 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Antacid Alone</title>
            <description>Calcium carbonate/magnesium hydroxide, single dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal</title>
          <description>Participant reported severity of heartburn using a Visual Analog Scale (VAS)directly on CRF every 15 minutes until no heartburn reported or up to 5 hours after 1st heartburn-inducing meal, whichever occurred first. At this point in time, a diary was provided to participants to record any changes in severity of heartburn for 28 hours post treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O3" value="1" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Heartburn After the Heartburn-inducing Meals</title>
        <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Product</title>
            <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
          </group>
          <group group_id="O2">
            <title>PPI Alone</title>
            <description>Lansoprazole 15 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Antacid Alone</title>
            <description>Calcium carbonate/magnesium hydroxide, single dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Heartburn After the Heartburn-inducing Meals</title>
          <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="62.8" upper_limit="75.8"/>
                    <measurement group_id="O2" value="61.2" lower_limit="51.6" upper_limit="70.7"/>
                    <measurement group_id="O3" value="59.1" lower_limit="50.5" upper_limit="67.8"/>
                    <measurement group_id="O4" value="56.9" lower_limit="50.4" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Nighttime Heartburn</title>
        <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Product</title>
            <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
          </group>
          <group group_id="O2">
            <title>PPI Alone</title>
            <description>Lansoprazole 15 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Antacid Alone</title>
            <description>Calcium carbonate/magnesium hydroxide, single dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Nighttime Heartburn</title>
          <description>Heartburn severity was measured using a Visual Analog Scale, which was 100 milliimeters long.
0 millimeters: None (no heartburn) 100 millimeters: Most severe</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="0.4" upper_limit="16.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="-1.0" upper_limit="15.0"/>
                    <measurement group_id="O3" value="4.7" lower_limit="-0.9" upper_limit="10.2"/>
                    <measurement group_id="O4" value="4.0" lower_limit="-1.6" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure: Number of Participants That Reported an Adverse Event for the Combination Product, PPI Alone, Antacid Alone and Placebo.</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Product</title>
            <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
          </group>
          <group group_id="O2">
            <title>PPI Alone</title>
            <description>Lansoprazole 15 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Antacid Alone</title>
            <description>Calcium carbonate/magnesium hydroxide, single dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Measure: Number of Participants That Reported an Adverse Event for the Combination Product, PPI Alone, Antacid Alone and Placebo.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination Product</title>
          <description>Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet, single dose</description>
        </group>
        <group group_id="E2">
          <title>PPI Alone</title>
          <description>Lansoprazole 15 mg, single dose</description>
        </group>
        <group group_id="E3">
          <title>Antacid Alone</title>
          <description>Calcium carbonate/magnesium hydroxide, single dose</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head New Therapeutic Opportunities</name_or_title>
      <organization>Novartis</organization>
      <phone>973-503-8000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

